All Pharma News
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure

Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
PRESS RELEASE
24 Jul 2024
Share Share
Sage Therapeutics To Report Q2 2024 Financials On July 31

Sage Therapeutics To Report Q2 2024 Financials On July 31
BUSINESSWIRE
17 Jul 2024
Share Share
Sage`s dalzanemdor trial design leaves efficacy question unclear

Sage`s dalzanemdor trial design leaves efficacy question unclear
James Waldron FIERCE BIOTECH
11 Jun 2024
Share Share
Sage Therapeutics: Presenting At Goldman Sachs Healthcare Event

Sage Therapeutics: Presenting At Goldman Sachs Healthcare Event
BUSINESSWIRE
05 Jun 2024
Share Share
FDA Approves Oral Treatment for Postpartum Depression

FDA Approves Oral Treatment for Postpartum Depression
DRUGTOPICS
08 May 2024
Share Share
Sage Therapeutics to Participate in Upcoming May Investor Conferences

Sage Therapeutics to Participate in Upcoming May Investor Conferences
BUSINESSWIRE
07 May 2024
Share Share
Sage Therapeutics Q1 2024 Results, Pipeline/Business Progress

Sage Therapeutics Q1 2024 Results, Pipeline/Business Progress
BUSINESSWIRE
25 Apr 2024
Share Share
Sage focuses on successful launch of postpartum depression drug

Sage focuses on successful launch of postpartum depression drug
ENDPTS
25 Apr 2024
Share Share
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop

Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
REUTERS
18 Apr 2024
Share Share
Sage Therapeutics Q1 2024 Results On 4/25

Sage Therapeutics Q1 2024 Results On 4/25
BUSINESSWIRE
11 Apr 2024
Share Share